Subsequent therapy was described by <i>BRCA</i>m status.<h4>Results</h4>Among 3741 patients with HER2-negative eBC, 51% and 56% were <i>BRCA</i>m tested in 2022 and 2023, respectively, >99% for germline <i>BRCA</i>m, and including 70% of 509 patients with triple-negative breast cancer (TNBC) and 50% of 3232 patients with HR+/HER2-negative eBC. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.